Screening for Immune Compatibility Before Cell Therapy

Abstract

Screening for immune compatibility is a fundamental step in the safe and effective administration of cell-based therapies. With the rapid expansion of cellular therapeutics—ranging from hematopoietic stem cell transplantation (HSCT) to engineered cell products such as CAR-T cells—rigorous assessment of immunologic compatibility has become paramount to minimize adverse events, optimize engraftment, and improve clinical outcomes. This review discusses the scientific rationale, clinical protocols, and current evidence underpinning immune compatibility screening before cell therapy, emphasizing its practical implications in contemporary medical practice.

Introduction

Cell therapy, an evolving frontier in regenerative and personalized medicine, holds transformative potential for treating a wide range of hematological, oncological, and immunological disorders. However, the immunological interplay between donor cells and recipient immune systems introduces risks of rejection, graft-versus-host disease (GVHD), and treatment failure. Pre-therapy immune compatibility screening aims to mitigate these risks, guiding selection and preparation of both donors and recipients. This article examines the epidemiology, pathophysiology, clinical approach, and guideline recommendations concerning immune compatibility assessment in cell therapy.

Epidemiology / Disease Burden

Cell therapy is increasingly employed in treating malignancies, genetic disorders, and autoimmune diseases. Over 50,000 allogeneic HSCT procedures are performed globally each year, while CAR-T therapies are rising in prevalence for refractory hematologic malignancies. Challenges related to immune incompatibility remain a leading source of morbidity, notably acute and chronic GVHD (up to 50% in allogeneic HSCT) and primary graft failure. The burden is magnified in populations with limited donor diversity, further underscoring the critical need for robust compatibility screening.

Pathophysiology

Immune compatibility hinges on the interplay between the donor\'s cell-surface antigens and the recipient\'s immune surveillance mechanisms. Key determinants include human leukocyte antigen (HLA) profiles, minor histocompatibility antigens, and, increasingly, non-HLA immunogenetic factors such as killer-cell immunoglobulin-like receptors (KIRs). Disparities in these elements can trigger alloreactivity, leading to graft rejection or GVHD, and are also implicated in immune reconstitution and infection risk post-therapy. Mechanistically, T-cell and NK-cell responses are central mediators of compatibility outcomes.

Risk Factors

Risk factors for immune incompatibility include HLA mismatch (particularly at HLA-A, -B, -C, -DRB1, and -DQB1 loci), presence of donor-specific antibodies (DSAs), ABO incompatibility, and prior sensitization events (e.g., transfusions, pregnancies, previous transplants). Additional risks arise from disparities in minor histocompatibility antigens and polymorphisms in immune regulatory genes. Patient comorbidities, underlying disease, and conditioning regimens further modulate risk profiles, influencing screening strategies and the need for desensitization protocols.

Clinical Features

Immune incompatibility may be clinically silent at onset but often manifests as acute or chronic GVHD (skin, liver, gastrointestinal involvement), graft failure, delayed engraftment, and increased infectious complications. In CAR-T cell therapies, immune mismatch can lead to reduced efficacy, cytokine release syndrome, or neurotoxicity. Vigilant clinical and laboratory surveillance is critical post-infusion to promptly identify and manage these complications.

Diagnosis

Diagnostic assessment of immune compatibility relies on a combination of serological and molecular techniques. High-resolution HLA typing (DNA-based) is the cornerstone, supplemented by crossmatch assays (flow cytometry, complement-dependent cytotoxicity) to detect DSAs. Extended immunogenetic profiling—including KIR genotyping and evaluation of minor histocompatibility antigens—is increasingly utilized, especially in haploidentical or unrelated donor scenarios. Pre-transplant infectious disease screening and assessment for underlying immune dysregulation are essential adjuncts.

Treatment & Management

Management strategies for immune incompatibility focus on optimizing donor selection, desensitization (e.g., plasmapheresis, rituximab for DSA reduction), and individualized conditioning regimens. Post-infusion, immunosuppressive therapies (calcineurin inhibitors, methotrexate, ATG) are tailored based on compatibility risk. In cases of established GVHD or graft failure, escalation of immunosuppression, cellular immunotherapy, or consideration of repeat transplantation may be warranted. Early intervention and multidisciplinary management are critical to improving outcomes.

Recent Advances / Emerging Therapies

Recent advances include next-generation sequencing for ultra-high resolution HLA typing, single-cell immunophenotyping, and the use of machine learning to predict compatibility and outcomes. Novel immunomodulatory agents and targeted cell engineering are expanding the therapeutic armamentarium, enabling the development of hypoimmunogenic cell products and universal donor lines. Additionally, in vivo gene editing (e.g., CRISPR/Cas9) holds promise for mitigating immunogenicity and overcoming traditional compatibility barriers.

Guideline Recommendations

International guidelines from the EBMT, ASBMT, and NMDP emphasize comprehensive HLA matching, DSA screening, and tailored risk assessment for allogeneic cell therapy candidates. The use of high-resolution typing, standardized crossmatches, and extended immunogenetic profiling is recommended for unrelated or haploidentical transplants. Recommendations advocate multidisciplinary evaluation, robust informed consent, and integration of emerging technologies to enhance safety and efficacy.

Conclusion

Thorough screening for immune compatibility before cell therapy is essential for optimizing patient outcomes and minimizing complications such as GVHD and graft failure. Advances in immunogenetic assessment and therapeutic innovation are reshaping the landscape, enabling safer and more effective cell-based interventions. Continued research, guideline refinement, and collaborative practice will further improve the precision and success of cell therapy in clinical medicine.